Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Editor’s introduction to the initial issue of the sixth volume of GaBI Journal / Professor Philip D Walson, MD, USA/Germany

Letters to the Editor

Pricing strategies for pharmaceuticals in developing countries: what options do we have? / Nada Moustafa Abdel Rida, Qatar; Professor Mohamed Izham Mohamed Ibrahim, PhD, Qatar

Commentary

Strategies for pricing of pharmaceuticals and generics in developing countries / Brian Godman, BSc, PhD; Professor Mohamed Azmi Hassali, PhD

Patent expiry and costs for anticancer medicines for clinical use / Brian Godman, BSc, PhD; Claudia Wild, PhD; Alan Haycox, PhD

Current overview of biosimilars in Iran / Hamideh Aghajani-Lazarjani, PhD; Fereidoun Mahboudi, PhD, Iran

Original Research

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey / Jean-Baptiste Reiland, MSc; Barbara Freischem; Alexander Roediger, MA

The naming and labelling of biologicals – a survey of US physicians’ perspectives / Harry L Gewanter, MD, FAAP, FACR; Michael S Reilly, Esq

Do pricing and usage-enhancing policies for biosimilar medicines differ from generic policies? Findings from a PPRI survey with competent authorities in 42 countries / Sabine Vogler, PhD; Peter Schneider, MA

Bioequivalence study of two formulations of 60 mg daclatasivir in healthy volunteers / Sattam Turky AlGhodyyr, MSc;  Mohammad Khalil Mohammad, RPh., PhD; Sanabel Omar Dawabsheh; Mohammad Ali Abu Fara, MD; Majdi Naser Abu Al hajj; Rabab Fayyez Tayyem, PhD

Assessment of medicine quality in emerging markets: the changing face of inferior medicines over time / Roger Bate, USA; Lorraine Mooney, UK

The assessment of biosimilarity with SABE and IBE criteria under a switching/alternating design / Aijing Zhang, PhD; Associate Professor Jung-Ying Tzeng; Professor Shein-Chung Chow, PhD, USA (Biosimilarity and Interchangeability)

Review Article

Ocular emulsions and dry eye: a case study of a non-biological complex drug product delivered to a complex organ to treat a complex disease / Anu Gore, PhD; Mayssa Attar, PhD; Chetan Pujara, PhD; Sesha Neervannan, PhD

Generic immonusuppressants comparability studies / Marc Maliepaard, PhD; Professor Hubert G M Leufkens, PharmD, PhD, The Netherlands (Generic Immunosuppressants in Transplantation)

Perspective

Pharmacovigilance of biosimilars and other biologicals within the hospital: current practices and future challenges / Barbara OM Claus, PharmD, PhD; Tiene Bauters, PharmD, PhD; Annemie Somers, PharmD, PhD; Belgium

Opinion

Austrian medicines authority positive towards biosimilar interchangeability / Christoph Baumgärtel, MD, MSc

Generic immunosuppression in transplantation: a controversial analysis / Jacques Rottembourg, MD

Special Report

Interchangeability of biosimilars in the US and around the world / Michelle Derbyshire, PhD, GaBI Online Editor

Patent expiry dates for biologicals: 2016 update / Michelle Derbyshire, PhD, GaBI Online Editor

Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and USA / Subramanian Venkatesan, MSc; Martine Lamfers, PhD; Sieger Leenstra, MD, PhD; Arnold G. Vulto, PharmD PhD FCP

Meeting Report

Roundtable on biosimilars: pharmacovigilance, traceability, immunogenicity, 15 November 2016, Madrid, Spain / Professor Francisco José de Abajo, MD, MPH, PhD; Professor Joan Albanell, MD; Olga Delgado Sanchez, PharmD; Kevin Klein, MSc; José Vicente Moreno-Muelas, MD; Sol Ruiz, PhD; Professor Maria Jesús Sanz Ferrando, PhD; Robin Thorpe, PhD, FRCPath; Professor Francisco Zaragozá, PhD

Biosimilar product labels in Europe: what information should they contain? / Alice Rolandini Jensen, MSci, GaBI Journal Editor

Roundtable on registries: practical considerations for registries – making them work, London, UK, 26 January 2017

Pharma News

Top developments in biosimilars during 2016 / Michelle Derbyshire, PhD, GaBI Online Editor

Abstracted Scientific Content

Generic prices estimated for four novel cancer drugs / Eleanor Bird, GaBI Journal Editor

Effective generics substitution / Maysoon Delahunty, GaBI Journal Editor

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL: http://gabi-journal.net/gabi-journal/forthcoming-issue


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048